Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer

BACKGROUND Advanced gastric cancer(AGC)remains a challenging malignancy with poor prognosis.The combination of oxaliplatin and trastuzumab has shown promising results in AGC treatment.This study aimed to investigate the effects of oxaliplatin and trastuzumab combination therapy on serum tumor markers and T lymphocyte subsets in patients with AGC and to explore their potential as predictive biomarkers for treatment response.AIM To investigate the impact of oxaliplatin and trastuzumab combination therapy on serum markers and T cell subsets in patients with AGC.METHODS This prospective study enrolled 60 patients with AGC.All patients received oxaliplatin(130 mg/m^(2),every 3 weeks)and trastuzumab(8 mg/kg loading dose,followed by 6 mg/kg every 3 weeks)for six cycles.Serum carcinoembryonic antigen(CEA),cancer antigen 19-9(CA19-9),and cancer antigen 72-4(CA72-4)were measured before and after treatment.T-lymphocyte subsets,including CD3+,CD4+,CD8+,and CD4+/CD8+ratios,were also evaluated.The clinical response was assessed using the Response Evaluation Criteria in Solid Tumors version 1.1.RESULTS After six cycles of treatment,the CEA,CA19-9,and CA72-4 serum levels significantly decreased compared to baseline levels(P<0.001).The percentages of CD3+and CD4+T lymphocytes increased significantly(P<0.05),whereas the percentage of CD8+T lymphocytes decreased(P<0.05).The CD4+/CD8+ratio also significantly increased after treatment(P<0.05).Patients with a higher decrease in serum tumor markers(≥50%reduction)and a higher increase in CD4+/CD8+ratio(≥1.5-fold)showed better clinical response rates(P<0.05).CONCLUSION Oxaliplatin and trastuzumab combination therapy effectively reduced serum tumor marker levels and modulated T lymphocyte subsets in patients with AGC.Combination therapy not only has a direct antitumor effect,but also enhances the immune response in patients with AGC.Serum tumor markers and T lymphocyte subsets may serve as potential predictive biomarkers for treatment response in patients with AGC receiving combination therapy.

Prognostic value and predictive model of tumor markers in stageⅠtoⅢgastric cancer patients

BACKGROUND Preoperative serum tumor markers have been widely used in the diagnosis and treatment of gastric cancer patients.However,few studies have evaluated the prognosis of gastric cancer patients by establishing statistical models with multiple serum tumor indicators.AIM To explore the prognostic value and predictive model of tumor markers in stage I and III gastric cancer patients.METHODS From October 2018 to April 2020,a total of 1236 patients with stage I to III gastric cancer after surgery were included in our study.The relationship between serum tumor markers and clinical and pathological data were analyzed.We established a statistical model to predict the prognosis of gastric cancer based on the results of COX regression analysis.Overall survival(OS)was also compared across different stages of gastric cancer.RESULTS The deadline for follow-up was May 31,2023.A total of 1236 patients were included in our study.Univariate analysis found that age,clinical stage,T and N stage,tumor location,differentiation,Borrmann type,size,and four serum tumor markers were prognostic factors of OS(P<0.05).It was shown that clinical stage,tumor size,alpha foetoprotein,carcinoembryonic antigen,CA125 and CA19-9(P<0.05)were independent prognostic factors for OS.According to the scoring results obtained from the statistical model,we found that patients with high scores had poorer survival time(P<0.05).Furthermore,in stage I patients,the 3-year OS for scores 0-3 ranged from 96.85%,95%,85%,and 80%.In stage II patients,the 3-year OS for scores 0-4 were 88.6%,76.5%,90.5%,65.5%and 60%.For stage III patients,3-year OS for scores 0-6 were 70.9%,68.3%,64.1%,50.9%,38.4%,18.5%and 5.2%.We also analyzed the mean survival of patients with different scores.For stage I patients,the mean OS was 55.980 months.In stage II,the mean OS was 51.550 months.The mean OS for stage III was 39.422 months.CONCLUSION Our statistical model can effectively predict the prognosis of gastric cancer patients.

Effect of Shenqi Fuzheng Injection combined with chemotherapy on peripheral blood cell level, tumor markers and immune function in patients with gastric cancer

Objective:To investigate the effects of Shenqi Fuzheng Injection combined with chemotherapy on peripheral blood cell level, tumor markers and immune function in patients with gastric cancer.Methods: Eighty patients with gastric cancer admitted to our hospital from May 2016 to October 2017 were selected as the research object and randomly divided into observation group and control group, 40 cases in each group. Control group was treated by DCF chemotherapy, while the observation group by Shenqi Fuzheng Injection based on the DCF chemotherapy. The levels of peripheral blood cells, tumor markers and immune function indexes in both groups were detected and compared before and after treatment.Results: There were no significant differences in serum RBC, WBC, PLT, Hb, NSE, CYFRA21-1, CA199, CEA, CD3+, CD4+, CD8+ and CD4+/CD8+ levels before treatment in both groups. Compared with the pretreatment group, the levels of RBC, WBC, PLT and Hb in both groups decreased to some extent after treatment, and the levels in the observation group were significantly higher than those in the control group;Compared with the same group before treatment, the levels of NSE, CYFRA21-1, CA199 and CEA in the two groups were significantly decreased, and the observation group was significantly lower than the control group;CD3+, CD4+, CD4+/CD8+ levels in control group and observation group increased to some extent after treatment, and the levels in observation group were significantly higher than those in control group. The levels of CD8+ in both groups after treatment were significantly lower than those before treatment, and the observation group was significantly lower than the control group after treatment. The above data for statistical analysis had significant differences.Conclusions: Shenqi Fuzheng injection combined with chemotherapy helps to clear and kill cancer cells, enhance immunity and reduce hematological toxicity after chemotherapy, which can be used as an adjuvant chemotherapy for gastric cancer.

Effect of arterial interventional chemotherapy before radical operation for gastric cancer on serum tumor markers and cell growth in the lesion

Objective:To investigate the effect of arterial interventional chemotherapy before radical operation for gastric cancer on serum tumor markers and cell growth in the lesion.Methods:90 patients with primary gastric cancer who underwent radical operation for gastric cancer in our hospital were chosen as the research subjects and divided into the control group (n=48) (did not receive preoperative arterial interventional chemotherapy) and the arterial interventional chemotherapy group (n=42) (received preoperative arterial interventional chemotherapy). The differences in tumor markers in serum as well as proliferation and apoptosis gene expression in gastric cancer tissues were compared.Results: Before surgery started, serum CA199, CA153, CA724 and AFP levels of arterial interventional chemotherapy group were significantly lower than those immediately after admission whereas serum CA199, CA153, CA724 and AFP levels of control group were not significantly different from those immediately after admission. After surgery, proliferation genes CUL4A and NTSR1 mRNA expression in gastric cancer tissues of arterial interventional chemotherapy group were lower than those of control group whereas DADS and FAM96B mRNA expression were higher than those of control group;apoptosis genes Livin and Bcl-2 mRNA expression were lower than those of control group whereas p53, p21 and Bax mRNA expression were higher than those of control group.Conclusion:Preoperative arterial interventional chemotherapy combined with radical operation for gastric cancer can more effectively inhibit the malignant degree of tumor and delay the growth of cancer cells.

Effect of S-1 combined with oxaliplatin on serum tumor markers,matrix metalloproteinase and immune function in elderly patients with gastric cancer

Objective: To investigate the effect of Compound Tegafur and Oteracil Potassium Sustained Capsules (S-1) combined with oxaliplatin chemotherapy on serum tumor marker matrix metalloproteinase and immune function in elderly patients with gastric cancer. Methods:According to the random data table, 80 cases of elderly patients with gastric cancer were divided into control group and observation group (n=40), patients in the control group were treated with oxaliplatin combined with Capecitabine Tablets, and the observation group patients were treated with S-1 combined with oxaliplatin, all treated for 6 cycles, before and after treatment, levels of serum tumor markers, matrix metalloproteinase and immune function were compared between the two groups. Results: Before treatment, there was no significant difference in the levels of CEA, CA125, CA19-9, MMP-2, MMP-9, CD3+, CD4+, CD8+and CD4+/CD8+between the two groups;After treatment, the levels of CEA, CA125, CA19-9, MMP-2, MMP-9 and CD8+in the two groups were significantly lower than those in the same group before treatment, and the levels of the observation group[(7.79±2.78) ng/mL, (22.56±7.31) U/mL, (13.48±3.05) U/mL, (57.84±8.93) ng/mL, (199.14±67.39) ng/mL and (26.21±4.18)%] were significantly lower than those in the control group;Compared with the group before treatment, the levels of CD3+, CD4+and CD4+/CD8+in the two groups were significantly increased, and the observation group [(66.89±5.84)%, (41.63±5.24)% and (1.37±0.29)] was significantly higher than the control group. Conclusion: S-1 combined with oxaliplatin chemotherapy can effectively reduce serum tumor markers and matrix metalloproteinase levels, improve immune function, has an important clinical value.

Study on the Correlation between the Detection of Tumor Markers in Abdominal Effusion and Chemotherapy Sensitivity

Since most patients with ovarian cancer are in the advanced stage when they are prone to recurrence,it is difficult to detect and treat ovarian cancer.There are tumor serum markers in the ascites.Therefore,the study explored the correlation between the serum marker levels of the ascites and chemotherapy sensitivity in patients with ovarian malignant tumors.First,50 patients with nested cancer were selected as research subjects and received treatment,and then immediately 200 mg carboplatin+100 mL normal saline was placed in the abdominal cavity of all patients,which was equivalent to an intraperitoneal chemotherapy.Carboplatin+docetaxel combined with intravenous chemotherapy was started 3 weeks after surgery,and chemotherapy was given every 3 weeks for a total of 5 to 6 courses.The serum levels of CA125,CA199,CEA and AFP in peripheral blood and peripheral blood were determined by ELISA.The results showed that the levels of CA125,CA199,CEA and AFP in serum and ascites after chemotherapy were lower than before chemotherapy(P<0.05).The short-term effective rate of 50 ovarian cancer patients(8 CR,28 PR,12 SD,2 PD)was 72.00%.Therefore,patients with ovarian malignant tumors had a good short-term curative effect after chemotherapy,which can reduce the ascites and serum levels of CA125,CA199,CEA,AFP for clinical reference value dual-mode MRI nanoparticle-mediated photothermal therapy showed good application potential in tumor treatment and diagnosis.

Laparoscopic vs open surgery for gastric cancer: Assessing time, recovery, complications, and markers

BACKGROUND Gastric cancer(GC)is one of the most common cancers worldwide.Morbidity and mortality have increased in recent years,making it an urgent issue to address.La-paroscopic radical surgery(LRS)is a crucial method for treating patients with GC;However,its influence on tumor markers is still under investigation.The data of 194 patients treated at Chongqing University Cancer Hospital bet-ween January 2018 and January 2019 were retrospectively analyzed.Patients who underwent traditional open surgery and LRS were assigned to the control(n=90)and observation groups(n=104),respectively.Independent sample t-tests andχ2 tests were used to compare the two groups based on clinical efficacy,changes in tumor marker levels after treatment,clinical data,and the incidence of posto-perative complications.To investigate the association between tumor marker levels and clinical efficacy in patients with GC,three-year recurrence rates in the two groups were compared.RESULTS Patients in the observation group had a shorter duration of operation,less in-traoperative blood loss,an earlier postoperative eating time,and a shorter hospital stay than those in the control group(P<0.05).No significant difference was observed between the two groups regarding the number of lymph node dissections(P>0.05).After treatment,the overall response rate in the control group was significantly lower than that in the observation group(P=0.001).Furthermore,after treatment,the levels of carbohydrate antigen 19-9,cancer antigen 72-4,carcinoembryonic antigen,and cancer antigen 125 decreased significantly.The observation group also exhibited a significantly lower incidence rate of postoperative complications compared to the control group(P<0.001).Additionally,the two groups did not significantly differ in terms of three-year survival and recurrence rates(P>0.05).CONCLUSION LRS effectively treats early gastric cancer by reducing intraoperative bleeding,length of hospital stays,and postoperative complications.It also significantly lowers tumor marker levels,thus improving the short-term prognosis of the disease.

Prognostic impact and reasons for variability by tumor location in gastric cancer

BACKGROUND Gastric cancer(GC)is a highly prevalent gastrointestinal tract tumor.Several trials have demonstrated that the location of GC can affect patient prognosis.However,the factors determining tumor location remain unclear.AIM To investigate the tumor location of patients,we went on to study the influencing factors that lead to changes in the location of GC.METHODS A retrospective evaluation was carried out on 3287 patients who underwent gastrectomy for GC in Zhejiang Cancer Hospital.The patients were followed up post-diagnosis and post-gastrectomy.The clinicopathological variables and overall survival of the patients were recorded.By analyzing the location of GC,the tumor location was divided into four categories:“Upper”,“middle”,“lower”,and“total”.Statistical software was utilized to analyze the relationship of each variable with the location of GC.RESULTS A total of 3287 patients were included in this study.The clinicopathological indices of gender,age,serum levels of carcinoembryonic antigen(CEA),carbohydrate antigen(CA19-9)and CA72-4 levels,were significantly associated with tumor location in patients with GC.In addition,there was a strong correlation between GC location and the prognosis of postoperative patients.Specifically,patients with“lower”and“middle”GC demonstrated a better prognosis than those with tumors in other categories.CONCLUSION The five clinicopathological indices of gender,age,CEA,CA19-9 and CA72-4 levels exhibit varying degrees of influence on the tumor location.The tumor location correlates with patient prognosis following surgery.

Potential prognostic,diagnostic and therapeutic markers for human gastric cancer

The high incidence of gastric cancer (GC) and its consequent mortality rate severely threaten human health. GC is frequently not diagnosed until a relatively advanced stage. Surgery is the only potentially curative treatment. Thus, early screening and diagnosis are critical for improving prognoses in patients with GC. Gastroscopy with biopsy is an appropriate method capable of aiding the diagnosis of specific early GC tumor types; however, the stress caused by this method together with it being excessively expensive makes it difficult to use it as a routine method for screening for GC on a population basis. The currently used tumor marker assays for detecting GC are simple and rapid, but their use is limited by their low sensitivity and specificity. In recent years, several markers have been identi&#x0fb01;ed and tested for their clinical relevance in the management of GC. Here, we review the serum-based tumor markers for GC and their clinical significance, focusing on discoveries from microarray/proteomics research. We also review tissue-based GC tumor markers and their clinical application, focusing on discoveries from immunohistochemical research. This review provides a brief description of various tumor markers for the purposes of diagnosis, prognosis and therapeutics, and we include markers already in clinical practice and various forthcoming biomarkers.

Effect of Xiaoaiping combined with intravenous chemotherapy on tumor marker levels and cell viability molecule expression in patients with advanced gastric cancer

Objective:To study the effect of Xiaoaiping combined with intravenous chemotherapy on tumor marker molecule content and cell viability molecule expression in patients with advanced gastric cancer. Methods:94 patients diagnosed with advanced gastric cancer in our hospital between May 2013 and March 2016 were selected and randomly divided into Xiaoaiping group and XELOX group who received Xiaoaiping combined with XELOX therapy and XELOX therapy alone respectively. After four cycles of treatment, serum was collected to detect tumor marker levels, and gastric cancer tissue was collected to detect the expression of invasion-, proliferation-and apoptosis-related molecules. Results:After four cycles of treatment, serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA199), thymidine kinase (TK)-1, Pentraxin-3 and human epididymis protein 4 (HE4) levels of Xiaoaiping group were significantly lower than those of XELOX group (P<0.05);ALDH1, CXCR4, CatE, CatS, CyclinD1, CDK4, CDC25B, Bcl-2 and Survivin expression in gastric cancer tissue of Xiaoaiping group were significantly lower than those of XELOX group (P<0.05) while Caspase-3, Caspase-9, PTEN and Beclin-1 expression were significantly higher than those of XELOX group (P<0.05). Conclusions:Xiaoaiping combined with intravenous chemotherapy for advanced gastric cancer can more effectively kill cancer cells and inhibit cancer cell proliferation and invasion.

Relationship of preoperative gastric cancer CT enhancement ratio and perfusion parameters with serum tumor marker levels and proliferation molecule expression in tumor lesions

Objective:To study the relationship of preoperative gastric cancer CT enhancement ratio and perfusion parameters with serum tumor marker levels and proliferation molecule expression in tumor lesions.Methods:A total of 68 patients with gastric cancer treated in the Second Hospital of Yulin City between May 2012 and May 2016 were chosen as observation group and sub-divided into early and middle gastric cancer group (n=41) and advanced gastric cancer group (n=27) according to the tumor stage;50 patients diagnosed with benign gastric diseases in our hospital during the same period were selected as benign gastric lesion group. CT enhancement rate and perfusion parameters of three groups of patients were detected by CT scan, serum tumor marker levels were evacuated by enzyme-linked immunosorbent assay (ELISA), and the proliferation gene mRNA expression levels were detected by RT-PCR method.Results: CER, AF, BV and CL levels of advanced gastric cancer group were higher than those of early and middle gastric cancer group and benign gastric lesion group;serum CA72-4, CA19-9, CA125 and CEA contents of advanced gastric cancer group were higher than those of early and middle gastric cancer group and benign gastric lesion group;CADM1, miRNA-34a and Cystatin M mRNA expression in tissue of advanced gastric cancer group were lower than those of early and middle gastric cancer group and benign gastric lesion group while Survivin and I2PP2A mRNA expression were higher than those of early and middle gastric cancer group and benign gastric lesion group. The Pearson test showed that the CT enhancement rate and perfusion parameters in patients with gastric cancer are directly correlated with the serum tumor marker levels and the proliferation gene expression in tumor lesions.Conclusion: Preoperative gastric cancer CT enhancement rate and perfusion parameters are directly related to the tumor malignancy, and can be used as a reliable method for the long-term tumor diagnosis and malignancy judgment.

Effect of depression on the immune function and tumor load in patients with advanced gastric cancer

Objective:To study the correlation between depression and immune function as well as tumor load in patients with advanced gastric cancer.Methods: 98 patients diagnosed with advanced gastric cancer in our hospital between May 2013 and September 2016 were selected and divided into depression group (n=39) with HAMD scores >50 and non-depression group with HAMD scores≤50 (n=39), serum was collected to detect the levels of cytokines interleukin-2 (IL-2), IL-4, IL-10, IL-17, interferon-γ (IFN-γ) and transforming growth factorβ1 (TGF-β1) as well as tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), CA724, TK-1 and sLAG-3, and gastric cancer tissues were collected to determine the expression of cell cycle-related proteins CyclinD1, CDK4 and E2F.Results:Serum IL-2, IFN-γand IL-17 levels of depression group were significantly lower than those of non-depression group (P<0.05) while IL-4, IL-10, TGF-β1, CEA, CA199, CA724, TK-1 and sLAG-3 levels were significantly higher than those of non-depression group (P<0.05);CyclinD1, CDK4 and E2F protein expression in tumor tissues of depression group were significantly higher than those of non-depression group (P<0.05).Conclusions:Depression can inhibit the anti-tumor immune response in patients with advanced gastric cancer, and then promote cancer cell proliferation and increase tumor load.

Effect of anxiety after chemotherapy on antitumor immune response and tumor load in patients with advanced gastric cancer

Objective:To study the effect of anxiety after chemotherapy on antitumor immune response and tumor load in patients with advanced gastric cancer.Methods:Patients with gastric cancer who received SOX chemotherapy in the First People's Hospital of Ziyang Sichuan Province between May 2012 and October 2015 were selected and divided into no anxiety group with HAMA score≤7 points, mild anxiety group with HAMA score 7-14 points, moderate anxiety group with HAMA score 14-21 points and severe anxiety group with HAMA score>21 points according to the HAMA score after four courses of chemotherapy. Cytokine and tumor marker levels in serum, immune cell levels in peripheral blood as well as proliferation gene expression in lesions were determined.Results: Peripheral blood Th1 levels as well as serum IL-2 and IFN-γ levels of mild anxiety group, moderate anxiety group and severe anxiety group were significantly lower than those of no anxiety group while peripheral blood Th2, Th17 and Treg levels as well as serum IL-4, IL-5, IL-17, IL-10, CEA, CA19-9, TK-1 and VEGF levels were significantly higher than those of no anxiety group, and EPHA2, c-myc and PCNA mRNA expression in tumor lesions were significantly higher than those of no anxiety group;the severer the anxiety, the lower the peripheral blood Th1 levels as well as serum IL-2 and IFN-γ levels, the higher the peripheral blood Th2, Th17 and Treg levels as well as serum IL-4, IL-5, IL-17, IL-10, CEA, CA19-9, TK-1 and VEGF levels, and the higher the EPHA2, c-myc and PCNA mRNA expression in tumor lesions.Conclusion:The aggravated anxiety in patients with advanced gastric cancer after chemotherapy will inhibit the antitumor immune response and increase the tumor load.

Effect of brucea javanica oil injection combined with neoadjuvant chemotherapy on malignant molecule expression and antitumor immune response in patients with gastric cancer

Objective:To study the effect of brucea javanica oil injection combined with neoadjuvant chemotherapy on malignant molecule expression and antitumor immune response in patients with gastric cancer.Methods: A total of 78 patients with gastric cancer undergoing preoperative neoadjuvant chemotherapy in our hospital between May 2013 and July 2016 were selected and randomly divided into two groups, intervention group received brucea javanica oil injection combined with neoadjuvant chemotherapy, and the control group accepted neoadjuvant chemotherapy. Serum tumor marker levels and peripheral blood regulatory molecule expression were determined before and after treatment, and the malignant molecule expression levels in gastric cancer lesions were determined after the operation.Results:2 cycles and 4 cycles after treatment, serum CEA, DKK1, exosc2 and ANXA2 levels of both groups of patients were significantly lower than those before treatment, PD-1, TIM-3 and Foxp3 mRNA expression in peripheral blood mononuclear cells of control group were significantly higher than those before treatment, PD-1, TIM-3 and Foxp3 mRNA expression in peripheral blood mononuclear cells of intervention group were significantly lower than those before treatment, serum CEA, DKK1, exosc2 and ANXA2 levels as well as PD-1, TIM-3 and Foxp3 mRNA expression in peripheral blood mononuclear cells of intervention group were significantly lower than those of control group, and the GKN1 and GKN2 mRNA expression in gastric cancer lesions were significantly higher than those of control group while GOLPH3 and PTP1B mRNA expression were significantly lower than those of control group.Conclusion:Brucea javanica oil injection combined with neoadjuvant chemotherapy can more effectively kill the gastric cancer cells and improve the antitumor immune response.

The Value of Blood Tumor Markers in the Prognosis of Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer before First-line Chemotherapy

Objective:To study the significance of CEA,CA199,CA72.4 and CA125 in the peripheral blood of patients with advanced or metastatic gastric cancer.Methods:The clinical data of 109 patients with non-operative local advanced or metastatic gastric cancer who received first-line chemotherapy in our center from July 2013 to May 2015,and the detection results of CEA,CA199,CA72.4 and CA125 tumor markers before chemotherapy were retrospectively collected,and their correlation with the clinicopathological characteristics and prognosis of the patients were analyzed.Results:The positive rates of CEA,CA199,CA72.4 and CA125 were 46.8%,40.2%,53.5%and 35.0%respectively in 109 cases of gastric cancer,and the positive rates of combined detection of four markers were 87.2%.CEA positive was significantly correlated with liver metastasis(P=0.014),CA125 positive with peritoneal metastasis(P=0.005).In univariate analysis,median PFS(6.3 months vs 11.1 months,P=0.020)and median OS(9.9 months vs 16.9 months,P=0.007)of CA72.4 positive subjects were significantly shorter than those of negative subjects,and median PFS(6.2 months vs 7.8 months,P=0.002)and median OS(9.8 months vs 15.6 months,P=0.009)of CA125 positive subjects were significantly shorter than those of negative subjects.95%CI 1.016-29.601).Of 109 patients,49(45.0%)were low-risk group(0 or 1 risk factor),60(55.0%)were high-risk group(2 to 4 risk factors).The median survival time of low-risk and high-risk groups was 18.5 months and 9.9 months,respectively(P=0.001).Conclusion:CA72.4 and CA125 are related to the prognosis of patients with local advanced or metastatic gastric cancer,and the prognosis model is helpful to stratify the risk of patients and provide the best treatment plan for each patient.

Comparative proteomics analysis of human gastric cancer

AIM: To isolate and identify differentially expressed proteins between cancer and normal tissues of gastric cancer by two-dimensional electrophoresis (2-DE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). METHODS: Soluble fraction proteins of gastric cancer tissues and paired normal tissues were separated by 2-DE. The differentially expressed proteins were selected and identified by MALDI-TOF-MS and database search. RESULTS: 2-DE profiles with high resolution and reproducibility were obtained. Twenty-three protein spots were excised from sliver staining gel and digested in gel by trypsin, in which fifteen protein spots were identified successfully. Among the identified proteins, there were ten over-expressed and five under-expressed proteins in stomach cancer tissues compared with normal tissues. CONCLUSION: In this study, the well-resolved, reproducible 2-DE patterns of human gastric cancer tissue and paired normal tissue were established and optimized and certain differentially-expressed proteins were identified. The combined use of 2-DE and MS provides an effective approach to screen for potential tumor markers.

Frequent loss of heterozygosity at 8p22 chromosomal region in diffuse type of gastric cancer

AIM: To study the loss of heterozygosity (LOH) at 8p21-23 locus in diffuse gastric cancer.METHODS: To evaluate the involvement of this region in gastric cancer, we used eight microsatellite markers covering two Mb of mentioned region, to perform a high-resolution analysis of allele loss in 42 cases of late diffuse gastric adenocarcinoma.RESULTS: Six of these STS makers: D8S1149, D8S1645, D8S1643, D8S1508, D8S1591, and D8S1145 showed 36%, 28%, 37%, 41%, 44% and 53% LOH, respectively.CONCLUSION: A critical region of loss, close to the NAT2 locus and relatively far from FEZ1 gene currently postulated as tumor suppressor gene in this region.

Serum Pepsinogen and Osteopontin for Gastric Cancer Screening

Objective： To investigate the value of combined assay of serum pepsinogen （PG） and osteopontin （OPN） levels for gastric cancer screening. Methods： Fasting serum pepsinogen Ⅰ, Ⅱ and OPN concentration were measured by ELISA in 570 subjects. The cut off points for PG and OPN were determined using ROC. Results： Using serum PGI concentration 〈80 ng/ml, Ⅰ, Ⅱ ration 〈5.0 and OPN concentration ≥34 ng/ml or ≥30.44 ng/ml （based on ROC） for gastric cancer screening had superior specificity, positive and negative predictive values compared with PG or OPN screening only. The sensitive and specificity of combining serum PG and OPN assay were both more than 70% compared with PG or OPN screening alone. Conclusion： Combining serum PG and OPN assay for gastric cancer screening is superior to PG or OPN level only. This may be a new method for gastric cancer mass screening.

Molecular mechanism of therapeutic approaches for human gastric cancer stem cells

Gastric cancer(GC)is a primary cause of cancer-related mortality worldwide,and even after therapeutic gastrectomy,survival rates remain poor.The presence of gastric cancer stem cells(GCSCs)is thought to be the major reason for resistance to anticancer treatment(chemotherapy or radiotherapy),and for the development of tumor recurrence,epithelial–mesenchymal transition,and metastases.Additionally,GCSCs have the capacity for self-renewal,differentiation,and tumor initiation.They also synthesize antiapoptotic factors,demonstrate higher performance of drug efflux pumps,and display cell plasticity abilities.Moreover,the tumor microenvironment(TME;tumor niche)that surrounds GCSCs contains secreted growth factors and supports angiogenesis and is thus responsible for the maintenance of the growing tumor.However,the genesis of GCSCs is unclear and exploration of the source of GCSCs is essential.In this review,we provide up-todate information about GCSC-surface/intracellular markers and GCSC-mediated pathways and their role in tumor development.This information will support improved diagnosis,novel therapeutic approaches,and better prognosis using GCSC-targeting agents as a potentially effective treatment choice following surgical resection or in combination with chemotherapy and radiotherapy.To date,most anti-GCSC blockers when used alone have been reported as unsatisfactory anticancer agents.However,when used in combination with adjuvant therapy,treatment can improve.By providing insights into the molecular mechanisms of GCSCs associated with tumors in GC,the aim is to optimize anti-GCSCs molecular approaches for GC therapy in combination with chemotherapy,radiotherapy,or other adjuvant treatment.

Latest therapeutic target for gastric cancer:Anthrax toxin receptor 1

Anthrax toxin receptor 1(ANTXR1),also known as tumor endothelial marker 8,is a highly conserved cell surface protein overexpressed in tumor-infiltrating vessels.It was first found in vascular endothelial cells of human colorectal cancer.Although our understanding of its physiological function is limited,it has been found that ANTXR1 binds collagen and promotes migration of endothelial cells in vitro.ANTXR1 is upregulated in vessels of different tumor types in mice and humans,and is also expressed by tumor cells themselves in some tumors,such as gastric,lung,intestinal and breast cancer.Developmental angiogenesis and wound healing were not disturbed in ANTXR1 knockout mice,but compared with wild-type mice,growth of melanoma was impaired after ANTXR1 knockout,indicating that host-derived ANTXR1 can promote tumor growth on the basis of immune activity.Previous studies have shown that ANTXR1 vaccines or sublethal doses of anthrax toxin can inhibit angiogenesis,slow tumor growth and prolong survival.These studies suggest that ANTXR1 is necessary for tumor rather than physiological angiogenesis.It has been found that ANTXR1 plays an important role in tumor angiogenesisas well as in the growth and metastasis of many kinds of tumors.This article reviews the physiological function of ANTXR1 and its role in different kinds of cancer.